VIR logo

VIR
Vir Biotechnology Inc

6,787
Mkt Cap
$1.55B
Volume
1.15M
52W High
$11.66
52W Low
$4.16
PE Ratio
-2.99
VIR Fundamentals
Price
$9.38
Prev Close
$9.19
Open
$9.24
50D MA
$9.55
Beta
1.68
Avg. Volume
1.8M
EPS (Annual)
-$3.16
P/B
1.86
Rev/Employee
$186,801.09
$464.19
Loading...
Loading...
News
all
press releases
Why a Biotech Fund Opened a New $6 Million Position in Vir Amid a 99% Stock Rally
Key PointsSuperstring Capital acquired 730,548 shares of Vir Biotechnology last quarter; the estimated trade size was $5.82 million based on quarterly average prices...
News Placeholder
More News
News Placeholder
Vir Biotechnology to Present Complete Week 96 Data from Phase 2 SOLSTICE Clinical Trial in Hepatitis Delta at the European Association for the Study of the Liver (EASL) Congress 2026
Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of tobevibart and elebsiran for chronic hepatitis delta...
News Placeholder
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million
Vir Biotechnology Stock Has Nearly Doubled in a Year. One Major Holder Just Trimmed $17 Million...
News Placeholder
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares...
News Placeholder
Vir Biotechnology's Chairman of the Board Sold 22,000 Company Shares. Here's What That Means for Investors.
Key PointsVicki Sato sold 22,000 shares on May 1, 2026, generating a transaction value of ~$221,000 at around $10.05 per share...
News Placeholder
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2026 Financial Results
Vir Biotechnology, Inc. (Nasdaq: VIR), today provided a corporate update and reported financial results for the first quarter ended March 31, 2026. Vir Bio delivered incredible momentum during the...
News Placeholder
Vir Biotechnology to Participate in Bank of America Securities 2026 Healthcare Conference
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that Marianne De Backer, M.Sc., Ph.D., MBA, Chief Executive Officer, will participate in a fireside chat at the Bank of America Securities 2026...
News Placeholder
Vir Biotechnology (NASDAQ:VIR) Director Vicki Sato Sells 22,000 Shares
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) Director Vicki Sato sold 22,000 shares of Vir Biotechnology stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $10.05, for a total transaction of $221,100.00. Following the transaction, the...
News Placeholder
Krystal Biotech, Inc. (KRYS) Tops Q1 Earnings and Revenue Estimates
Krystal Biotech (KRYS) delivered earnings and revenue surprises of +26.21% and +3.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
News Placeholder
Vir Biotechnology (VIR) Expected to Announce Quarterly Earnings on Wednesday
Vir Biotechnology (NASDAQ:VIR) will be releasing its Q1 2026 earnings after the market closes on Wednesday, May 6. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-5-6-vir-biotechnology-inc-stock...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available